Skip to main content

Analysts Conflicted on These Healthcare Names: Centene (CNC) and AbbVie (ABBV)

Tipranks - Tipranks - Wed Jan 28, 11:28AM CST

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Centene (CNC – Research Report) and AbbVie (ABBV – Research Report).

Claim 50% Off TipRanks Premium

Centene (CNC)

In a report released today, David S Macdonald from Truist Financial reiterated a Buy rating on Centene. The company’s shares closed last Tuesday at $41.20.

According to TipRanks.com, Macdonald is a 5-star analyst with an average return of 11.8% and a 59.5% success rate. Macdonald covers the Healthcare sector, focusing on stocks such as Guardian Pharmacy Services, Inc. Class A, Concentra Group Holdings Parent, Inc., and Ardent Health Partners, Inc. ;'>

The word on The Street in general, suggests a Hold analyst consensus rating for Centene with a $43.33 average price target, which is a -1.5% downside from current levels. In a report issued on January 16, Bernstein also maintained a Buy rating on the stock with a $59.00 price target.

See Insiders’ Hot Stocks on TipRanks >>

AbbVie (ABBV)

UBS analyst Michael Yee maintained a Hold rating on AbbVie yesterday. The company’s shares closed last Tuesday at $224.38.

According to TipRanks.com, Yee is a 1-star analyst with an average return of -0.5% and a 43.3% success rate. Yee covers the Healthcare sector, focusing on stocks such as Vertex Pharmaceuticals, MBX Biosciences, Inc., and Olema Pharmaceuticals. ;'>

Currently, the analyst consensus on AbbVie is a Moderate Buy with an average price target of $256.71, implying a 16.2% upside from current levels. In a report issued on January 20, Bernstein also maintained a Hold rating on the stock with a $225.00 price target.

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).